ReviewArquivos brasileiros de cardiologia2021
Update on the Treatment of Pulmonary Arterial Hypertension.
Review in Arquivos brasileiros de cardiologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Red Araça (Biomedicines · 2026Article
- 2025 Annual Review of Pulmonary Arterial Hypertension Clinical Research.Pulmonary therapy · 2026Review
- Selexipag for the treatment of schistosomiasis-associated pulmonary arterial hypertension: the SELSCH study.ERJ open research · 2026Article
- Impact of combined exercise training in peripheral and diaphragm muscles and in mortality in a preclinical model of pulmonary arterial hypertension.Pflugers Archiv : European journal of physiology · 2025Article
- Prognostic Role of Platelets in Pulmonary Arterial Hypertension.Pulmonary circulation · 2025Article
- Exercise Right Heart Catheterization: The Key to Unraveling the Mystery of Recurrent Syncope.JACC. Case reports · 2025Article
- Upfront combination therapy with sildenafil and ambrisentan in patients with chronic thromboembolic pulmonary hypertension.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Article
- Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension.Current vascular pharmacology · 2024Review
- Electrocardiogram as a Predictor of Mortality in Individuals with Pulmonary Hypertension.Arquivos brasileiros de cardiologia · 2024Article
- Why Multitarget Vasodilatory (Endo)cannabinoids Are Not Effective as Antihypertensive Compounds after Chronic Administration: Comparison of Their Effects on Systemic and Pulmonary Hypertension.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Riociguat: An Alternative to Treat Pulmonary Hypertension.Arquivos brasileiros de cardiologia · 2022Article
- Should we Consider the Stimulation of Soluble Guanylyl Cyclase as Beneficial for Treating Pre-Capillary Pulmonary Hypertension?Arquivos brasileiros de cardiologia · 2022Article
- Pterostilbene after Acute Myocardial Infarction: Effect on Heart and Lung Tissues.Arquivos brasileiros de cardiologia · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last decades, important advances have been made in the treatment of pulmonary arterial hypertension (PAH), a severe, progressive, incurable, and potentially fatal disease. For an adequate therapy, correct hemodynamic diagnosis and etiology classification are fundamental. Many etiologies - rheumatic disease, portal hypertension, congenital heart diseases, schistosomiasis - require specific measures, in addition to drug therapy for PAH. The specific therapy for PAH is based on medications that act on three pathophysiological pathways - prostacyclin, endothelin, and nitric oxide pathways. These drugs have multiple presentations (oral, intravenous, subcutaneous, and inhaled) and have changed the history of PAH. This review presents an overview of drug therapy strategies and different forms and peculiarities of PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.